• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by ALPS Group Inc

    2/4/26 9:14:49 PM ET
    $ALPS
    Get the next $ALPS alert in real time by email
    6-K 1 form6-k.htm 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of February 2026

     

    Commission File Number: 001-42915

     

    Alps Group Inc

    (Registrant’s Name)

     

    Unit E-18-01 & E-18-02, Level 18, Icon Tower (East)

    No. 1, Jalan 1/68F, Jalan Tun Razak

    50400 Kuala Lumpur

    Wilayah Persekutuan, Malaysia

    (Address of Principal Executive Offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    Alps Group Inc (the “Company”) is filing this Report on Form 6-K to report its financial results for the six months ended September 30, 2025 and to discuss its recent corporate developments.

     

    Attached as exhibits to this Report on Form 6-K are:

     

    (1)The unaudited pro forma condensed combined financial information and related notes of Alps Group Inc, Alps Life Sciences Inc and Globalink Investment Inc as at September 30 2025 as Exhibit 99.1;
      
    (2)The unaudited financial statements and related notes of Alps Group Inc for the six months ended September 30, 2025 as Exhibit 99.2:
      
    (3)The unaudited consolidated financial statements and related notes of Alps Life Sciences Inc for the six months ended September 30, 2025 as Exhibit 99.3;
      
    (4)The unaudited condensed consolidated financial statements and related notes of Globalink Investment Inc for the nine months ended September 30, 2025 as Exhibit 99.4;
      
    (5)Management’s Discussion and Analysis of Financial Condition and Results of Operations of Alps Life Sciences Inc for the six months ended September 30, 2025 as Exhibit 99.5;

      

     

     

     

    SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

     

    Statements in this current report with respect to the Company’s current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of the Company. Forward-looking statements include, but are not limited to, those statements using words such as “believe,” “expect,” “plans,” “strategy,” “prospects,” “forecast,” “estimate,” “project,” “anticipate,” “aim,” “intend,” “seek,” “may,” “might,” “could” or “should,” and words of similar meaning in connection with a discussion of future operations, financial performance, events or conditions. From time to time, oral or written forward-looking statements may also be included in other materials released to the public. These statements are based on management’s assumptions, judgments and beliefs in light of the information currently available to it. The Company cautions investors that a number of important risks and uncertainties could cause actual results to differ materially from those discussed in the forward-looking statements, including but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the Company with the Securities and Exchange Commission. Therefore, investors should not place undue reliance on such forward-looking statements. Actual results may differ significantly from those set forth in the forward-looking statements.

     

    All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

     

    Financial Statements and Exhibits.

     

    The following exhibits are being filed herewith:

     

    99.1   The unaudited pro forma condensed combined financial information and related notes of Alps Group Inc, Alps Life Sciences Inc and Globalink Investment Inc as at September 30 2025
    99.2   The unaudited financial statements and related notes of Alps Group Inc for the six months ended September 30, 2025
    99.3   The unaudited consolidated financial statements and related notes of Alps Life Sciences Inc for the six months ended September 30, 2025
    99.4   The unaudited condensed consolidated financial statements and related notes of Globalink Investment Inc for the nine months ended September 30, 2025

    99.5

      Management’s Discussion and Analysis of Financial Condition and Results of Operations of Alps Life Sciences Inc for the six months ended September 30, 2025

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Alps Group Inc
         
    Date: February 4, 2026 By: /s/ Dr. Tham Seng Kong
      Name:  Dr. Tham Seng Kong
      Title: Chief Executive Officer and Director

     

     

    Get the next $ALPS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALPS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ALPS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alps Group Inc Announces Potential Pipeline Expansion Beyond CELESOME(+) Following Publication of Nebulized Human Umbilical Cord Mesenchymal Stem Cell Exosome Therapy

    KUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the "Company" or "Alps Group"), the parent company of Alps Life Sciences Inc. ("Alps Holdco"), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced a potential expansion of its exosome-related pipeline beyond its previously disclosed CELESOME(+) program. The announcement follows the publication of a preliminary retrospective clinical case series in SAGE Open Medical Case Reports describing nebulized human umbilical cord mesenchymal stem cell ("hUCMSC") derived exosome in patient with asthma and/or chronic obstructive pulmonar

    1/30/26 8:00:00 AM ET
    $ALPS

    Alps Group Inc Appoints Cheing Lye-Ping as Chief Financial Officer

    KUALA LUMPUR, Malaysia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (NASDAQ:ALPS) (the "Company" or "Alps Group"), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced the appointment of Cheing Lye-Ping (Penny) as Chief Financial Officer (CFO) of the Company, effective January 5, 2026. Ms. Cheing will be responsible for leading the development of the financial strategy to support the business, including investment strategies and long-term financial plans. She will also oversee financial budgeting, planning and analysis, audit, and tax compliance for Alps Group and subsidiaries, as well as ris

    1/8/26 8:00:00 AM ET
    $ALPS

    Alpine Announces Status of Sale Process

    Nashville, Tennessee and Vancouver, British Columbia--(Newsfile Corp. - June 21, 2023) - Alpine Summit Energy Partners, Inc. (TSXV:ALPS) (NASDAQ:ALPS) ("Alpine Summit" or the "Company") today announced that its Board of Directors unanimously voted to conclude its previously announced asset sale process, which was being conducted by Stephens Inc. ("Stephens").Beginning on March 8, 2023, Stephens broadly solicited expressions of interest in a sale of various strategic, highly productive assets recently developed and proven by the Company. After considering several bids, the Company's Board of Directors concluded that the bids were not reflective of the value of the underlying assets and it wa

    6/21/23 7:15:00 PM ET
    $ALPS

    $ALPS
    SEC Filings

    View All

    SEC Form 6-K filed by ALPS Group Inc

    6-K - Alps Group Inc (0002025774) (Filer)

    2/4/26 9:14:49 PM ET
    $ALPS

    SEC Form 6-K filed by ALPS Group Inc

    6-K - Alps Group Inc (0002025774) (Filer)

    1/30/26 4:00:28 PM ET
    $ALPS

    SEC Form 424B3 filed by ALPS Group Inc

    424B3 - Alps Group Inc (0002025774) (Filer)

    1/21/26 4:00:52 PM ET
    $ALPS

    $ALPS
    Leadership Updates

    Live Leadership Updates

    View All

    Alps Group Inc Appoints Cheing Lye-Ping as Chief Financial Officer

    KUALA LUMPUR, Malaysia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (NASDAQ:ALPS) (the "Company" or "Alps Group"), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced the appointment of Cheing Lye-Ping (Penny) as Chief Financial Officer (CFO) of the Company, effective January 5, 2026. Ms. Cheing will be responsible for leading the development of the financial strategy to support the business, including investment strategies and long-term financial plans. She will also oversee financial budgeting, planning and analysis, audit, and tax compliance for Alps Group and subsidiaries, as well as ris

    1/8/26 8:00:00 AM ET
    $ALPS

    $ALPS
    Financials

    Live finance-specific insights

    View All

    Alpine Summit Energy Partners Announces Full Year 2022 Financial and Operating Results

    Nashville, Tennessee and Vancouver, British Columbia--(Newsfile Corp. - March 27, 2023) - Alpine Summit Energy Partners, Inc. (TSXV:ALPS) (NASDAQ:ALPS) ("Alpine Summit" or the "Company") is pleased to announce its financial and operating results for the year ended December 31, 2022. Alpine Summit's audited consolidated financial statements and notes, as well as management's discussion and analysis (the "MD&A") and its Annual Report on Form 10-K for the year ended December 31, 2022 will be available under the Company's issuer profile at "www.sedar.com" and "www.sec.gov/edgar", as well as on the Company's website at "www.alpinesummitenergy.com".Craig Perry, Chief Executive Officer, remarked:

    3/27/23 7:00:00 AM ET
    $ALPS

    Alpine Summit Energy Partners Announces Strategic Review of Assets

    Nashville, Tennessee and Vancouver, British Columbia--(Newsfile Corp. - February 23, 2023) - Alpine Summit Energy Partners, Inc. (TSXV:ALPS) (NASDAQ:ALPS) ("Alpine Summit" or the "Company") today announced that the Board of Directors is commencing a strategic review of its assets. The Company seeks to facilitate a timely and orderly response to unsolicited inquiries by other upstream oil and gas companies who have expressed interest in acquiring various assets of the Company. The goal of the review is to maximize shareholder value and better position the Company for long-term stability and growth.Given the Company's decision to initiate this strategic review, alongside the historic volatil

    2/23/23 8:00:00 AM ET
    $ALPS

    Alpine Summit Energy Partners Announces February 2023 Dividend

    Nashville, Tennessee and Vancouver, British Columbia--(Newsfile Corp. - February 1, 2023) - Alpine Summit Energy Partners, Inc. (TSXV:ALPS) (NASDAQ:ALPS) ("Alpine Summit" or the "Company") is pleased to announce that, in accordance with its current monthly dividend policy, the Board of Directors of the Company has declared a dividend of US$0.0315 per subordinate voting share for the month of February 2023. Simultaneously with declaring the dividend on the subordinate voting shares, the directors also declared a dividend on the Company's multiple voting shares equal to US$3.15 per share and a dividend on the Company's proportionate voting shares equal to US$0.0315 per share.The dividend is pa

    2/1/23 8:00:00 AM ET
    $ALPS